Distribution of ELOVL4 in the developing and adult mouse brain
Open accessAbstract
ELOngation of Very Long chain fatty acids (ELOVL)-4 is essential for the synthesis of very long chain-fatty acids (fatty acids with chain lengths ≥ 28 carbons). The functions of ELOVL4 and its very long-chain fatty acid products are poorly understood at present. However, mutations in ELOVL4 cause neurodevelopmental or neurodegenerative diseases that vary according to the mutation and inheritance pattern. Heterozygous inheritance of different ELOVL4 mutations causes Stargardt-like Macular Dystrophy or Spinocerebellar Ataxia type 34. Homozygous inheritance of ELOVL4 mutations causes more severe disease characterized by seizures, intellectual disability, ichthyosis, and premature death. To better understand ELOVL4 and very long chain fatty acid function in the brain, we examined ELOVL4 expression in the mouse brain between embryonic day 18 and postnatal day 60 by immunolabeling using ELOVL4 and other marker antibodies. ELOVL4 was widely expressed in a region- and cell type-specific manner, and was restricted to cell bodies, consistent with its known localization to endoplasmic reticulum. ELOVL4 labeling was most prominent in grey matter, although labeling also was present in some cells located in white matter. ELOVL4 was widely expressed in the developing brain by embryonic day 18 and was especially pronounced in regions underlying the lateral ventricles and other neurogenic regions. The basal ganglia in particular showed intense ELOVL4 labeling at this stage. In the postnatal brain, cerebral cortex, hippocampus, cerebellum, thalamus, hypothalamus, midbrain, pons and medulla all showed prominent ELOVL4 labeling, although ELOVL4 distribution was not uniform across all cells or subnuclei within these regions. In contrast, the basal ganglia showed little ELOVL4 labeling in the postnatal brain. Double labeling studies showed that ELOVL4 was primarily expressed by neurons, although presumptive oligodendrocytes located in white matter tracts also showed labeling. Little or no ELOVL4 labeling was present in astrocytes or radial glial cells. These findings suggest that ELOVL4 and its very long chain fatty acid products are important in many parts of the brain and that they are particularly associated with neuronal function. Specific roles for ELOVL4 and its products in oligodendrocytes and myelin and in cellular proliferation, especially during development, are possible.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retina and cerebellum exhibit the highest expression levels of ELOVL4, the elongase responsible for synthesizing VLCFAs.
“Notably, these two tissues exhibit the highest expression levels of ELOVL4, the elongase responsible for synthesizing VLCFAs (Yeboah et al., 2021; Sherry et al., 2017).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Sherry et al., 2017
The Introduction identifies ELOVL4 as the enzyme needed to synthesize very-long-chain fatty acids and lists both brain and retina among tissues where it is expressed. The Results (Distribution of ELOVL4 in specific brain regions; page unavailable) report that cerebellar granule-layer neurons had the most intense labeling of any cells in the brain. The paper does not establish that the retina and cerebellum are the two highest-expressing tissues overall. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system
Sunkin, S. M., Ng, L., Lau, C., Dolbeare, T., Gilbert, T. L., Thompson, C. L., Hawrylycz, M., & Dang, C. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1042 · Cited by 796 · see citing works
Functional diversity of astrocytes in neural circuit regulation
Haim, L. B., & Rowitch, D. H. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.159 · Cited by 618 · see citing works
Retinal very long-chain PUFAs: new insights from studies on ELOVL4 protein
Agbaga, M.-P., Mandal, M. N. A., & Anderson, R. E. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r005025 · Cited by 167 · see citing works
Aveldaño, M. I. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)75767-6 · Cited by 142 · see citing works
Impaired neurotransmission in ether lipid-deficient nerve terminals
Brodde, A., Teigler, A., Brugger, B., Lehmann, W. D., Wieland, F., Berger, J., & Just, W. W. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds097 · Cited by 57 · see citing works
A New<i>ELOVL4</i>Mutation in a Case of Spinocerebellar Ataxia With Erythrokeratodermia
Bourassa, C. V., Raskin, S., Serafini, S., Teive, H. A. G., Dion, P. A., & Rouleau, G. A. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0888 · Cited by 42 · see citing works
Flagged first, then by citations
Research works printed but not linked: 36
- Agbaga M. P. (2016). Different mutations in ELOVL4 affect very long chain fatty acid biosynthesis to cause variable neurological disorders in humans. Adv. Exp. Med. Biol. 854, 129– 135. 10.1007/978-3-319-17121-0_18 26427403 · DOI
- Agbaga M. P. Brush R. S. Mandal M. N. Henry K. Elliott M. H. Anderson R. E. (2008). Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. Proc. Natl. Acad. Sci. U.S.A. 105, 12843– 12848. 10.1073/pnas.0802607105 18728184 PMC2525561 · DOI
- Aldahmesh M. A. Mohamed J. Y. Alkuraya H. S. Verma I. C. Puri R. D. Alaiya A. A.. (2011). Recessive mutations in ELOVL4 cause ichthyosis, intellectual disability, and spastic quadriplegia. Am. J. Hum. Genet. 89, 745– 750. 10.1016/j.ajhg.2011.10.011 22100072 PMC3234380 · DOI
- Ambasudhan R. Wang X. Jablonski M. M. Thompson D. A. Lagali P. S. Wong P. W.. (2004). Atrophic macular degeneration mutations in ELOVL4 result in the intracellular misrouting of the protein. Genomics 83, 615– 625. 10.1016/j.ygeno.2003.10.004 15028284 · DOI
- Aveldano M. I. Sprecher H. (1987). Very long-chain (C-24 to C-36) polyenoic fatty-acids of the N − 3 and N − 6 series in dipolyunsaturated phosphatidylcholines from bovine retina. J. Biol. Chem. 262, 1180– 1186. 3805016
- Bennett L. D. Brush R. S. Chan M. Lydic T. A. Reese K. Reid G. E.. (2014). Effect of reduced retinal VLC-PUFA on rod and cone photoreceptors. Invest. Ophthalmol. Vis. Sci. 55, 3150– 3157. 10.1167/iovs.14-13995 24722693 PMC4027810 · DOI
- Bernstein P. S. Tammur J. Singh N. Hutchinson A. Dixon M. Pappas C. M.. (2001). Diverse macular dystrophy phenotype caused by a novel complex mutation in the ELOVL4 gene. Invest. Ophthalmol. Vis. Sci. 42, 3331– 3336. 11726641
- Cadieux-Dion M. Turcotte-Gauthier M. Noreau A. Martin C. Meloche C. Gravel M.. (2014). Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia. JAMA Neurol. 71, 470– 475. 10.1001/jamaneurol.2013.6337 24566826 · DOI · Paper page
- Cameron D. J. Tong Z. Z. Yang Z. L. Kaminoh J. Kamiyah S. Chen H. Y.. (2007). Essential role of Elovl4 in very long chain fatty acid synthesis, skin permeability barrier function, and neonatal survival. Int. J. Biol. Sci. 3, 111– 119. 10.7150/ijbs.3.111 17304340 PMC1796949 · DOI
- Debus E. Weber K. Osborn M. (1983). Monoclonal antibodies specific for glial fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides. Differentiation 25, 193– 203. 10.1111/j.1432-0436.1984.tb01355.x 6198232 · DOI
- Edwards A. O. Donoso L. A. Ritter R. III. (2001). A novel gene for autosomal dominant Stargardt-like macular dystrophy with homology to the SUR4 protein family. Invest. Ophthalmol. Vis. Sci. 42, 2652– 2663. 11581213
- Grayson C. Molday R. S. (2005). Dominant negative mechanism underlies autosomal dominant Stargardt-like macular dystrophy linked to mutations in ELOVL4. J. Biol. Chem. 280, 32521– 32530. 10.1074/jbc.M503411200 16036915 · DOI
- Hopiavuori B. R. Agbaga M. P. Brush R. S. Sullivan M. T. Sonntag W. E. Anderson R. E. (2017). Regional changes in CNS and retinal glycerophospholipid profiles with age - A molecular blueprint. J. Lipid Res. 58, 668– 680 10.1194/jlr.M070714 28202633 PMC5392743 · DOI
- Jackson C. L. Walch L. Verbavatz J. M. (2016). Lipids and their trafficking: an integral part of cellular organization. Dev. Cell 39, 139– 153. 10.1016/j.devcel.2016.09.030 27780039 · DOI
- Karan G. Yang Z. Zhang K. (2004). Expression of wild type and mutant ELOVL4 in cell culture: subcellular localization and cell viability. Mol. Vis. 10, 248– 253. 15073583
- Kentroti S. Baker R. Lee K. Bruce C. Vernadakis A. (1991). Platelet-activating factor increases glutamine synthetase activity in early and late passage C-6 glioma cells. J. Neurosci. Res. 28, 497– 506. 10.1002/jnr.490280406 1678434 · DOI
- Lein E. S. Hawrylycz M. J. Ao N. Ayres M. Bensinger A. Bernard A.. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168– 176. 10.1038/nature05453 17151600 · DOI · Paper page
- Li W. Sandhoff R. Kono M. Zerfas P. Hoffmann V. Deng B. C.. (2007). Depletion of ceramides with very long chain fatty acids causes defective skin permeability barrier function, and neonatal lethality in ELOVL4 deficient mice. Int. J. Biol. Sci. 3, 120– 128. 10.7150/ijbs.3.120 17311087 PMC1796950 · DOI
- Logan S. Agbaga M. P. Chan M. D. Brush R. S. Anderson R. E. (2014). Endoplasmic reticulum microenvironment and conserved histidines govern ELOVL4 fatty acid elongase activity. J. Lipid Res. 55, 698– 708. 10.1194/jlr.M045443 24569140 PMC3966703 · DOI
- Logan S. Agbaga M. P. Chan M. D. Kabir N. Mandal N. A. Brush R. S.. (2013). Deciphering mutant ELOVL4 activity in autosomal-dominant stargardt macular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 110, 5446– 5451. 10.1073/pnas.1217251110 23509295 PMC3619277 · DOI
- Mandal M. N. Ambasudhan R. Wong P. W. Gage P. J. Sieving P. A. Ayyagari R. (2004). Characterization of mouse orthologue of ELOVL4: genomic organization and spatial and temporal expression. Genomics 83, 626– 635. 10.1016/j.ygeno.2003.09.020 15028285 · DOI
- Marchette L. D. Sherry D. M. Brush R. S. Chan M. Wen Y. Wang J.. (2014). Very long chain polyunsaturated fatty acids and rod cell structure and function. Adv. Exp. Med. Biol. 801, 637– 645. 10.1007/978-1-4614-3209-8_80 24664753 PMC4456017 · DOI
- Marza E. Lesa G. M. (2006). Polyunsaturated fatty acids and neurotransmission in Caenorhabditis elegans. Biochem. Soc. Trans. 34, 77– 80. 10.1042/BST0340077 16417487 · DOI
- Marza E. Long T. Saiardi A. Sumakovic M. Eimer S. Hall D. H.. (2008). Polyunsaturated fatty acids influence synaptojanin localization to regulate synaptic vesicle recycling. Mol. Biol. Cell 19, 833– 842. 10.1091/mbc.E07-07-0719 18094048 PMC2262990 · DOI
- McMahon A. Butovich I. A. Mata N. L. Klein M. Ritter R. III. Richardson J.. (2007). Retinal pathology and skin barrier defect in mice carrying a Stargardt disease-3 mutation in elongase of very long chain fatty acids-4. Mol. Vis. 13, 258– 272. 17356513 PMC2633486
- McMahon A. Lu H. Butovich I. A. (2014). A role for ELOVL4 in the mouse meibomian gland and sebocyte cell biology. Invest. Ophthalmol. Vis. Sci. 55, 2832– 2840. 10.1167/iovs.13-13335 24677106 PMC4008046 · DOI
- Mir H. Raza S. I. Touseef M. Memon M. M. Khan M. N. Jaffar S.. (2014). A novel recessive mutation in the gene ELOVL4 causes a neuro-ichthyotic disorder with variable expressivity. BMC Med. Genet. 15: 25. 10.1186/1471-2350-15-25 24571530 PMC3941482 · DOI
- Mullen R. J. Buck C. R. Smith A. M. (1992). NeuN, a neuronal specific nuclear protein in vertebrates. Development 116, 201– 211. 1483388
- Ozaki K. Doi H. Mitsui J. Sato N. Iikuni Y. Majima T.. (2015). A novel mutation in elovl4 leading to spinocerebellar ataxia (SCA) with the hot cross bun sign but lacking erythrokeratodermia: a broadened spectrum of SCA34. JAMA Neurol. 72, 797– 805. 10.1001/jamaneurol.2015.0610 26010696 · DOI · Paper page
- Poulos A. Johnson D. W. Beckman K. White I. G. Easton C. (1987). Occurrence of unusual molecular species of sphingomyelin containing 28-34-carbon polyenoic fatty acids in ram spermatozoa. Biochem. J. 248, 961– 964. 10.1042/bj2480961 3435495 PMC1148644 · DOI
- Poulos A. Sharp P. Johnson D. Easton C. (1988). The occurrence of polyenoic very long chain fatty acids with greater than 32 carbon atoms in molecular species of phosphatidylcholine in normal and peroxisome-deficient (Zellweger's syndrome) brain. Biochem. J. 253, 645– 650. 10.1042/bj2530645 2845926 PMC1149355 · DOI
- Robinson B. S. Johnson D. W. Poulos A. (1990). Unique molecular species of phosphatidylcholine containing very-long-chain (C24-C38) polyenoic fatty acids in rat brain. Biochem. J. 265, 763– 767. 10.1042/bj2650763 2306213 PMC1133699 · DOI
- Rotstein N. P. Pennacchiotti G. L. Sprecher H. Aveldano M. I. (1996). Active synthesis of C24:5, n-3 fatty acid in retina. Biochem. J. 316(Pt 3), 859– 864. 10.1042/bj3160859 8670163 PMC1217429 · DOI
- Vasireddy V. Uchida Y. Salem N. Jr. Kim S. Y. Mandal M. N. Reddy G. B.. (2007). Loss of functional ELOVL4 depletes very long-chain fatty acids (≥C28) and the unique ω-O-acylceramides in skin leading to neonatal death. Hum. Mol. Genet. 16, 471– 482. 10.1093/hmg/ddl480 17208947 PMC1839956 · DOI
- Wolf H. K. Buslei R. Schmidt-Kastner R. Schmidt-Kastner P. K. Pietsch T. Wiestler O. D.. (1996). NeuN: a useful neuronal marker for diagnostic histopathology. J. Histochem. Cytochem. 44, 1167– 1171. 10.1177/44.10.8813082 8813082 · DOI
- Zhang K. Kniazeva M. Han M. Li W. Yu Z. Yang Z.. (2001). A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat. Genet. 27, 89– 93. 10.1038/84765 11138005 · DOI
Cited by
Sorted by citations
The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models
Dawes, M. L., Haberlander, J. P., Islinger, M., & Schrader, M. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1602343 · Cited by 7 · see citing works
- Authors
- Sherry, D. M., Hopiavuori, B. R., Stiles, M. A., Rahman, N. S., Ozan, K. G., Deak, F., Agbaga, M.-P., & Anderson, R. E.
- Affiliations
- University of Oklahoma Health Sciences Center (US)
- Dean McGee Eye Institute (US)
- Corresponding author
- Sherry, David M.
- Venue
- Frontiers in Neuroanatomy
- Publisher
- Frontiers Media SA
- Published
- 2017-05-01
- Volume
- 11
- Pages
- 38-38
- ISSN
- 1662-5129 (ISSN-L)
- PMC
- PMC5410580
- OpenAlex
- W2611077407
- Cited by
- 38
- References
- 6
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 10 · 2022: 3 · 2021: 10 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 2
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Neuroanatomy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Neurological Disorders and Stroke (R21 NS090117, F31 NS089358)
- National Eye Institute (P30 EY021725)
- Knights Templar Eye Foundation
- BrightFocus Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- ELOVL4, very long chain fatty acids, brain development, mouse brain, neuronal expression, oligodendrocytes, white matter, basal ganglia, endoplasmic reticulum, neurodevelopmental disorders, myelin, cell proliferation, neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review